BMS pulls new diabetes med in Germany

Share this article:

Bristol-Myers Squibb and AstraZeneca chased Thursday's warm-and-fuzzy FDA panel endorsement news of its type 2 diabetes medication with a splash of cold water Friday when they announced they were pulling the drug from the German market, where it is known as Forxiga (dapagliflozin). The companies said they have not had agreeable pricing discussions with local insurers and are walking away.

The drug's Dec. 13 endorsement was a redemption of sorts—an FDA panel turned the drug makers away in 2001 over safety concerns. Briefing documents indicated that reviewers were still worried about bladder cancer.

Share this article:
close

Next Article in Business Briefs

Email Newsletters

More in Business Briefs

Avastin pockets another Priority Review label

It's the second for this cancer drug in two weeks.

Court invalidates some healthcare subsidies

The lawsuit has been wending its way through the courts for a while, and, although it is being deliberated in several other venues, the decision is part of a legal dispute that puts patients in the 36 states offering federal exchanges in limbo.

FDA generic division overhaul kicks in

The Food and Drug Administration has been intent on elevating and reorganizing its office of Generic Drugs since 2012.